Rapid-acting insulin analogues in type 1 diabetics: What guidelines recommend

The use of rapid-acting insulin analogues in the treatment of type 1 diabetes is recommended in numerous national and international guidelines, in which the various advantages of rapid-acting insulin analogues are described as follows: they reduce the incidence of hypoglycaemia; they lower the post-prandial blood sugar values; they allow more flexibility in the daily life of the patients; and they are associated with greater treatment satisfaction (Canadian and American Diabetes Associations, NICE, ISPAD). The guidelines especially recommend the use of rapid-acting insulin analogues in children and adolescents, as well as patients using pump therapy. The new OF guidelines emphasize the value of insulin analogues in reducing the post-prandial blood sugar surge. For physicians, the implementation of rapid-acting insulin analogues in patients with type 1 diabetes is an indispensible option, especially in view of individual tailoring of therapy and improvement in quality of life. This is reflected in numerous national and international guidelines.